INTRODUCTION
============

*MYH9*-related disease (*MYH9*-RD) is a genetic disorder of autosomal dominant inheritance caused by mutations of the *MYH9* gene, which encodes the non-muscle myosin heavy chain IIA (NMMHC-IIA) on chromosome 22q12. Around 200 affected families have been described in the literature, which suggest a very low prevalence of this disease.

*MYH9*-RD is characterized by congenital macrothrombocytopenia, leading to bleeding tendency, along with cytoplasmic inclusion bodies within leukocytes (Döhle-like inclusions), sensorineural deafness, cataracts, and nephropathy. The latter usually presents at a juvenile age with proteinuria, sometimes causing nephrotic syndrome, with or without microhematuria. It often progresses to end-stage renal disease (ESRD).[@B1]

Herein, we sought to describe the case of a young male patient affected by *MYH9*-RD that developed nephrotic-range proteinuria, microhematuria, and rapid loss of kidney function.

CASE DESCRIPTION
----------------

A twenty-year-old male has been followed up at the Clinic Hospital of Federal University of Paraná due to medical history of epistaxis, ecchymosis, and petechiae since infancy. At first, Bernard-Soulier syndrome was suspected due to macrothrombocytopenia and tendency of bleeding. When he was 17 years old, hearing loss and hypertension were detected along with mild renal failure, microhematuria and nephrotic-range proteinuria. Renal biopsy could not be performed due to risk of bleeding (platelets count: 7000/µL). Cataracts were excluded by ophthalmological evaluation. Due to the clinical suspicion of *MYH9*-RD, genotyping of the patient and of his parents was performed. A *de novo* missense mutation in exon 1 of the *MYH9* gene \[c.287C \> T; p.Ser(TCG)96(TTG)Leu\] was detected ([Figure 1](#f1){ref-type="fig"}). Actually, neither his parents nor his brother and sister had clinical manifestation of *MYH9*-RD. Enalapril (20 mg/day) was initiated for renal protection. The patient did not adhere to treatment and was lost to follow-up. Two years later, he returned to the outpatient clinic complaining of foamy urine, peripheral edema, and hypertension (160/120 mmHg). Laboratory tests detected worsening of renal function and persistent proteinuria. [Table 1](#t1){ref-type="table"} shows the evolution of laboratory parameters during the follow-up.

Figure 1Molecular test of the index case and of his parents; Footnote: a *de novo* heterozygous c.287C\>T in exon 1 of *MHY9* \[p.Ser(TCG)96(TTG) Leu\] was detected (i). His father (ii) and his mother (iii) did not have the mutation.

###### Laboratory evolution.

  Laboratory               June 2012   March 2013   June 2015   June 2017
  ------------------------ ----------- ------------ ----------- -----------
  creatinine (mg/dL)       0.9         1.2          1.7         3.4
  eGFR (mL/min/1.73m^2^)   126         88.4         57.2        24.4
  urea (mg/dL)             34          27           32          80
  proteinuria (g/24h)      NA          7.5          5.5         5.7
  albumin (g/dL)           3.4         3.1          3.5         3.1
  cholesterol (mg/dL)      185         205          249         241
  platelets count (n/µL)   4000        7000         6500        3000

Abbreviations: eGFR: CKD-EPI estimated glomerular filtration rate; NA: not available.

DISCUSSION
==========

*MYH9*-RD is characterized by congenital macrothrombocytopenia associated with variable degrees of sensorineural hearing loss, pre-senile cataract, and renal disease. Nephropathy occurs in approximately 30% of the patients with *MYH9*-RD and has a progressive and severe evolution. It usually presents at a juvenile age with proteinuria, sometimes causing nephrotic syndrome, with or without microhematuria. Our patient presented all clinical manifestation of *MYH9*-RD, but cataract. In most patients, nephropathy progresses to ESRD before the fourth decade of life.[@B1]

A genotype-phenotype correlation has been recognized in *MYH9*-RD. A higher incidence and a worse prognosis of kidney impairment have been associated with mutations affecting the head domain of NMMHC-IIA, compared with mutations in tail domain.[@B2] Most patients with *MYH9*-RD present an autosomal dominant inheritance, and around 30% of them have a *de novo* mutation.[@B1] Our patient presented a de novo missense mutation in exon 1 of *MYH9* \[c.287C \> T; p.Ser(TCG)96(TTG)Leu\] in the head domain. To date, more than 30 mutations within the 40 exons of the *MYH9* gene have been detected, among them the one of our patient.[@B3] In agreement with the genotype-phenotype correlation, our patient developed a rapid deterioration of renal function. The decline per year of the glomerular filtration rate was 20 mL/min/1.73m^2^ during the last five years.

Due to the overlap of clinical manifestations, *MYH9*-RD associated with renal impairment was considered a variant of Alport syndrome, designated as Fechtner syndrome. Recently, these syndromes were recognized as distinct disorders. They can be distinguished by the presence of thrombocytopenia, the hallmark of *MYH9*-RD and not a feature of Alport syndrome. Moreover, the latter is caused by mutations in the *COL4A3, COL4A4*, and *COL4A5* genes, leading mainly to alterations in the glomerular basement membrane.[@B4] The clinical features together with the presence of a pathogenic mutation in the *MYH9* gene allowed a prompt and reliable diagnosis of *MYH9*-RD.

Renal biopsy is not usually performed in *MYH9*-nephropathy because of the risk of bleeding, reserved for cases in which the differential diagnosis is necessary. Renal histopathological findings are variable and unspecific, encompassing mesangial expansion or proliferation and segmental glomerulosclerosis. Electron microscopy commonly reveals glomerular basement membrane thickening and podocyte foot process effacement[@B1]. The pathogenesis of *MYH9*-nephropathy is not completely understood. NMMHC-IIA is an important component of podocyte foot process. Thus, *MYH9*-nephropathy may result from an alteration in the podocyte cytoskeleton.[@B5]

Blockade of the renin-angiotensin system might be effective in reducing proteinuria and slowing the progression of *MYH9* nephropathy.[@B6] As our patient did not adhere to the treatment, we could not evaluate the efficacy of this strategy, though.

To the best of our knowledge, this is the first case of *MYH9*-nephropathy described in Brazil. The learning points of this case need to be highlighted. In case of macrothrombocytopenia of uncertain diagnosis, urinalysis must be performed and proteinuria should be monitored to start renin-angiotensin system blockage as early as possible. Genotyping is a valuable tool for guiding diagnosis and prognosis. Finally, awareness of rare genetic kidney disorders is essential to ensure accurate diagnosis and proper management of orphan disease patients.
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